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Introduction: Many patients with coronary heart disease (CHD) who achieve target low
density lipoprotein cholesterol (LDL-C) values still experience vascular events because of
a residual vascular risk due to other risk factors, particularly non-LDL-C dyslipidemia,
because of non-adherence to non-pharmacological  and pharmacological management.
Method and aims: We used simple markers and inexpensive screening tools for metabolic
disorders associated with insulin resistance and metabolic syndrome identifying subjects at
a high cardiovascular (CV) risk – atherogenic dyslipidemia [triglycerides (TG) ≥2.0 mmol/l
and high-density lipoprotein cholesterol (HDL-C) ≤1.0 mmol/l in males and ≤1.2 mmol/l in
females], hypertriglyceridemic waist (TG ≥2.0 mmol/l and waist circumference ≥90 cm in
males and ≥85 cm in females), atherogenic index of plasma [AIP = log (TG/HDL-C)] and non-
HDL-C (non-HDL-C = total cholesterol  HDL-C)]. We focused on the development of these
risk factors among patients with established stable CHD over more than the last 16 years.
Results: We examined 1484 patients, 1152 males (78%) and 332 females (22%) from the Czech
parts of EUROASPIRE I–IV (EA I–IV) surveys. In males, TG, HDL-C, and non-HDL-C decreased
signiﬁcantly from EA I to IV (p for trends NS; 0.0001; 0.0001, respectively). In females, there
was no change in TG; HDL-C, and non-HDL-C decreased signiﬁcantly (p for trends NS; 0.03;
0.0001, respectively). Atherogenic dyslipidemia prevalence decreased signiﬁcantly in both
sexes (p for trends 0.004 and 0.0012, respectively). Hypertriglyceridemic  waist prevalence
showed no change in either sex. There were no signiﬁcant changes in AIP risk strata in either
sex. About 30–40% of males and 24–30% of females had their AIP in the high-risk strata,
which tended to increase in males. The prevalence of type 2 diabetes (T2DM) and waist
circumference increased signiﬁcantly from EAI to IV (from 23% to 48%, and from 98 cm to
105 cm, respectively; both p for trend <0.0001). The prevalence of all above mentioned
residual vascular risk markers was higher in patients with T2DM and impaired fasting
glucose than in those with normal fasting glucose in both sexes.
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Conclusion: Despite the increase in T2DM prevalence and waist circumference from EA I to IV,
hypertriglyceridemic waist prevalence showed no change and atherogenic dyslipidemia
prevalence decreased signiﬁcantly in both sexes, because not all obese patients are insulin-
resistant and not all patients with glucose metabolism disorders present all characteristics of
metabolic syndrome. Simple markers of the atherogenic phenotype, especially AIP, should be
used in CV risk assessment.
# 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp. z o.o.
All rights reserved.
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.Introduction
Coronary heart disease belongs to the most common causes of
death in the Czech Republic and most other European countries
[1]. The EUROASPIRE (EA) surveys are independent sentinel
surveys designed to provide a unique European picture of
preventive action by cardiologists, other specialists, and general
practitioners to determine whether the European guidelines on
CHD prevention are being implemented adequately [2–5]. It is
well known that not all CHD patients achieve the recommended
target values for conventional risk factors [especially low-
density lipoprotein cholesterol (LDL-C), elevated blood pressure,
hyperglycemia,  etc.], and do not actually adhere to lifestyle
recommendations  (especially quitting smoking, regular physi-
cal activity, and low-fat diet). While, on the one hand, part of the
residual CV risk may be due to the failure to achieve target
values even in individuals receiving standard therapy; over-
weight or obesity with visceral adipose tissue accumulation,
glucose metabolism disorders and dyslipidemia beyond LDL-C
(especially high TG and low HDL-C) make up just another part of
the residual vascular risk [6]. Moreover, a meta-analysis of statin
studies with more than 90,000 patients has shown that these
patients with CHD and ‘‘around’’ target LDL-C values still
experience vascular events because of the residual vascular risk
due to other risk factors, especially non-LDL-C dyslipidemia [7].
The sedentary lifestyle and high-calorie diet, features of lifestyle
typical also of the Czech population, increase the incidence of
overweight, obesity, and other metabolic disorders such as
metabolic syndrome and T2DM that make up an important part
of the residual vascular risk seen in patients treated for
conventional CV risk factors [8,9].
The majority of CHD patients in the EA surveys were treated
by statins and ACE inhibitors, beta-blockers, and other
antihypertensive drugs possibly masking the metabolic
syndrome criteria according to the latest ‘‘harmonized’’
deﬁnition [10]. That was why we used the hypertriglyceridemic
waist – a simple marker (and an inexpensive  screening tool) for
metabolic disorders associated with insulin resistance, the
main pathophysiological background of metabolic syndrome
and T2DM. Hypertriglyceridemic  waist identiﬁes subjects at
high risk for CHD [11–13]. Apolipoprotein B (Apo-B) reﬂecting
the number of all atherogenic particles including typical
insulin-resistant dyslipidemia (i.e., small dense LDL particles,
IDL, intermediate-density lipoprotein, VLDL, very-low-density
lipoprotein) was not measured in the EA surveys, in which case
estimation of non-HDL-C is recommended [14]. We alsoassessed at the atherogenic index of plasma (AIP) deﬁned as
logarithmic transformation of molar TG and HDL-C concen-
trations. This index seems to be most useful in assessing
residual risk due to insulin-resistant dyslipidemia; according
to the authors of this index, AIP is closely related to the size of
HDL-C, LDL-C and VLDL-C particles considered new-genera-
tion CV risk markers that deﬁne the atherogenic plasma
genotype more accurately than the classical biochemical
markers; AIP can be used for monitoring the current lipopro-
tein proﬁle and predicting CV risk [15,16].
In the present analysis, we focused on investigating
markers of residual CV risk, determined by non-HDL-C,
atherogenic (insulin-resistant)  dyslipidemia, hypertriglyceri-
demic waist, and AIP among patients with established stable
CHD over the last 16 years.
Method
Patient samples of the Czech parts EA I–IV were described in a
previous paper by Mayer Jr. et al. For our part of research, total
cholesterol (T-C), TG, HDL-C, and other biochemical parameters
were determined by an enzymatic autoanalyzer (Beckman
Coulter AU 680, Beckman Coulter Inc., USA). Low-density
lipoprotein cholesterol was calculated using the Friedewald
equation for TG ≤4.5 mmol/l. Low HDL-C was deﬁned as
≤1.0 mmol/l in males and ≤1.2 mmol/l in females. Elevated
triglycerides were deﬁned as ≥2.0 mmol/l. Atherogenic dyslipi-
demia was deﬁned as a combination of the two above
parameters.
Non-HDL-C was calculated using the formula Non-HDL-
C = TC – HDL-C (mmol/l). The target value for non-HDL-C in
patients with CHD is <2.6 mmol/l [14].
Hypertriglyceridemic  waist was deﬁned as TG ≥2.0 mmol/l
and waist circumference ≥90 cm in males and ≥85 cm in
females [11,12]. Waist circumference was measured at the
midpoint between the lowest rib and the iliac crest at a light
expiration [13].
The atherogenic index of plasma, AIP = log [TG/HDL-C] is
based on laboratory ﬁndings concerning the mechanism of
regulation of the size of lipoproteins. Subjects with established
CHD were divided into three risk strata according to their AIP:
low risk 0.3 to 0.10, intermediate risk 0.11 to 0.24, and high
risk >0.24 [15,16]; AIP can be calculated simply online [17].
Statistical methods used in the results analyses included
the Mann–Whitney test, multivariate logistic regression, and
Kruskal–Wallis ANOVA.
Table 2 – Parameters of insulin resistant dyslipidemia.
Parameter p for trend
EA I (n = 207) EA II (n = 297) EA III (n = 341) EA IV (n = 307)
Mean SD Mean SD Mean SD Mean SD
Males Triglycerides (mmol/l) 2.02 1.26 1.71 0.93 1.91 2.18 1.94 1.2 0.07
HDL cholesterol (mmol/l) 1.23 0.3 1.18 0.34 1.21 0.3 1.12 0.25 0.0001
non-HDL-cholesterol (mmol/l) 4.2 0.92 4.47 1.18 3.37 1.28 3.19 0.95 0.0001
EA I (n = 86) EA II (n = 105) EA III (n = 79) EA IV (n = 62) p for trend
Mean SD Mean SD Mean SD Mean SD
Females Triglycerides (mmol/l) 1.85 1.23 1.77 0.94 2.19 2 1.65 0.82 NS
HDL cholesterol (mmol/l) 1.38 0.35 1.43 0.47 1.31 0.27 1.23 0.23 0.03
non-HDL-cholesterol (mmol/l) 4.2 0.92 4.45 1.18 3.45 1.32 3.22 0.97 0.0001
EA – EUROASPIRE; SD – standard deviation.
Table 1 – Basic characteristics of the sample.
Parameter EA I EA II EA III EA IV p for trend
Mean SD Mean SD Mean SD Mean SD
Total (n) 293 402 420 369
Males/females (n, %) 207/86 (71/29) 297/105 (74/26) 341/79 (81/19) 307/62 (83/17) 0.0001
Age (years) 59 8 59 8 60 7 62 7 0.0001
BMI (kg/m2) 28.6 4.2 29.5 4.6 29.6 4.7 29.5 4.3 0.01
Waist circumference (cm) 98 12 99 11 102 12 105 12 0.0001
Systolic BP (mmHg) 144 22 137 20 144 20 135 18 0.0001
Diastolic BP (mmHg) 87 11 81 11 86 12 82 10 0.0001
Current smoker (n, %) 81 (24) 82 (20) 98 (24%) 81 (22%) NS
Total cholesterol (mmol/l) 5.4 0.9 5.7 1.24 4.66 1.34 4.36 1.01 0.0001
Glycemia (mmol/l) 6.5 2.5 7 2.3 7.4 2.6 7 2 0.05
LDL cholesterol (mmol/l) 3.39 0.82 3.68 1.09 2.66 0.91 2.37 0.8 0.0001
Betablockers (n, %) 189 (57) 303 (74) 371 (88) 324 (87) 0.0001
ACE-inhibitors (n, %) 79 (24) 193 (47) 312 (74) 301 (81) 0.0001
Statins (n, %) 23 (7) 160 (39) 350 (83) 346 (93) 0.0001
Fibrates (n, %) 68 (23) 74 (18) 10 (2) 5 (1) 0.0001
Antidiabetics (n, %) 33 (10) 49 (12) 80 (19) 112 (30) 0.0001
Diabetes history (n, %) 78 (23) 103 (25) 190 (45) 179 (48) 0.0001
Impaired fasting glucose (n, %) 66 (20) 131 (32) 131 (31) 60 (16) 0.0001
EA – EUROASPIRE; SD – standard deviation; BMI – body mass index; BP – blood pressure.
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We examined a total of 1484 patients, 1152 males (78%) and 332
females (22%) participating in the Czech parts of EA I-IV. Basic
characteristics of patients with stable CHD are given in Table 1.
Age, body mass index (BMI), waist circumference, glycemia,
T2DM, and impaired fasting glucose prevalence, antidiabetic
and secondary preventive drug (beta-blockers, ACE inhibitors,
statins) use increased signiﬁcantly from EA I to EA IV. On the
other hand, systolic and diastolic blood pressure, T-C and LDL-
C concentrations and treatment with ﬁbrates decreased
signiﬁcantly over time. There was no change in smoking
habits in patients with stable CDH over the 16 years.
Focusing on parameters of non-LDL dyslipidemia, mean
plasma TG concentrations were quite stable in both sexes,
mean HDL-C decreased especially signiﬁcantly in males. Mean
non-HDL-C decreased signiﬁcantly from EA I to IV in either sex
(Table 2). About one in three patients had either low HDL-C orhigh TG. Atherogenic dyslipidemia was present in between 10
and 20%, and there was a strong decrease in prevalence in both
sexes during the last 16 years. Hypertriglyceridemic waist was
present in about one third of the sample and showed no
change from EA I to EA IV in both sexes (Table 3). The three risk
strata of AIP are shown in Fig. 1. There were no signiﬁcant
changes in AIP-related risk strata observed in both sexes from
EA I to EA IV. About 30–40% of males and 24–30% of females
had AIP in the high-risk strata, with an increasing trend of
borderline signiﬁcance in males.
There was a steep increase in T2DM prevalence in either
sex from EAI to IV. While one in four patients with CHD had
from T2DM in EA I and II, nearly half of patients with CHD had
T2DM in EA III and IV. After that we divided all survey subjects
according to glucose level groups: normal fasting glucose
<5.6 mmol/l; impaired fasting glucose 5.6–6.9 mmol/l; hyper-
glycemia ≥7.0 mmol/l or use of antidiabetic drugs. We looked
for any relationships of the investigated residual vascular risk
markers according to glucose levels (Table 4). Mean AIP value
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Fig. 1 – Percentage of males (a) and females (b) in categories of AIP in EA studies p for trend 0.06 (a) and NS (b),
EA – EUROASPIRE, AIP – atherogenic index of plasma, log (triglycerides/HDL-cholesterol), NS – non significant.
Table 3 – Trends of residual risk markers from EA I to EA IV in males.
Parameter Percentage (%) of patients in each EA survey p for trend
EA I EA II EA III EA IV
Males Low HDL-C 37 28 33 33 NS
Elevated TG 38 28 29 32 0.08
Atherogenic DLP 21 11 12 13 0.0004
HyTG waist 33 27 27 27 NS
Females Low HDL-C 34 35 32 45 NS
Elevated TG 31 33 30 21 NS
Atherogenic DLP 21 11 12 14 0.0012
HyTG waist 33 27 28 29 NS
EA – EUROASPIRE; low HDL-C – low HDL-cholesterol (≤1.0 mmol/l in males and ≤1.2 mmol/l in females); elevated TG – elevated triglycerides
(≥2.0 mmol/l); high non-HDL-C – high non-HDL-cholesterol (≥2.6 mmol/l); atherogenic DLP – atherogenic dyslipidemia (low HDL-C and elevated
TGs); HyTG waist – hypertriglyceridemic waist (elevated TG and waist ≥90 cm in males and ≥85 cm in females).
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C concentrations increased signiﬁcantly in males, but not in
females. Atherogenic dyslipidemia prevalence was signiﬁ-
cantly higher in patients with hyperglycemia in males and
females than in patients with normal and impaired fasting
glucose. Hypertriglyceridemic waist prevalence increased
signiﬁcantly with glycemia in males from 20 to 38%, and from
23 to 38% in females.Discussion
We examined patients with stable CHD included in the Czech
parts of four independent (EA I–IV) surveys conducted in 1996,
2000, 2006 and 2012, and their metabolic markers of residual
CV risk. We found no signiﬁcant difference in the prevalence of
hypertriglyceridemic waist as a surrogate of insulin resistance
Table 4 – Residual risk markers according to glucose metabolism.
Parameter Glucose metabolism categories
<5.6 mmol/l 5.6–6.9 mmol/l ≥7.0 mmol/l or antidiabetics =
treatment for diabetes
Mean SD Mean SD Mean SD p for trend
Males AIP 0.11 0.27 0.12 0.25 0.21 0.27 <0.0001
non-HDL-C (mmol/l) 3.27 1.8 3.77 1.1 3.51 1.34 0.001
Atherogenic DLP (%) 10 11 18 0.001
HyTG waist (%) 20 24 38 <0.0001
Females AIP 0.0002 0.25 0.07 0.25 0.19 0.27 <0.0001
non-HDL-C (mmol/l) 3.9 1.9 3.9 1.34 3.92 1.48 NS
Atherogenic DLP (%) 11 10 20 0.03
HyTG waist (%) 23 23 38 0.007
AIP – atherogenic index of plasma, log (TG/HDL cholesterol); non-HDL-C – non-HDL-cholesterol; non-HDL-C – non-HDL-cholesterol; atherogenic
DLP – atherogenic dyslipidemia (HDL-C ≤1.0 mmol/l in males and ≤1.2 mmol/l in females and triglycerides ≥2.0 mmol/l); HyTG waist –
hypertriglyceridemic waist (triglycerides ≥2.0 mmol/l and waist ≥90 cm in males and ≥85 cm in females).
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Atherogenic dyslipidemia (TG ≥2 mmol/l in combination with
low HDL-C ≤1.0 mmol/l in males and ≤1.2 mmol/l in females)
were documented in 21% patients with CHD in EA I and
signiﬁcantly less in EA II, III, and IV in either sex (11–14%, p for
trends 0.004 and 0.0012, respectively). There were no obvious
changes in the prevalence of increased AIP calculated as log
(TG/HDL-C) in both sexes in all EAs; an increasing trend of
borderline signiﬁcance was seen only in males. Non-HDL-C
was signiﬁcantly lower in EA III and IV in comparison with EA I
and II, due mainly to the LDL-C decrease as TG and HDL-C
concentrations were relatively stable in all groups of patients.
There was a steep increase in T2DM prevalence in both sexes
in EA I–IV (from 25% to 50%). The prevalence of hypertrigly-
ceridemic waist, atherogenic dyslipidemia, non-HDL-C and,
also, AIP were signiﬁcantly higher in patients with T2DM or
impaired fasting glucose as compared with patients with
normal fasting glucose.
Except of a huge improvement in invasive procedures and
prescription of statins, ACE inhibitors, beta-blockers, and
antithrombotic drugs during the last 16 years, there is still a big
potential for non-pharmacological approach and achieving
recommended goals of conventional risk factors among
patients in secondary CV prevention, as shown in the previous
paper by O. Mayer Jr. et al. in this issue of Cor et Vasa.
Unhealthy lifestyle habits – a high calorie diet, low physical
activity, and no change in smoking habit (22% patients still
smoke) – in Czech patients with CHD contribute to the
increasing prevalence of overweight, obesity, and hyperglyce-
mia (thus contributing to manifestation of T2DM). In Czech
patients with stable CHD included into the EAs, T2DM
prevalence increased steeply since 2006. It is generally
accepted that diabetic patients have 2–4 times higher CV risk
(higher in females than in males) than non-diabetic subjects
[18]. On the other hand, CHD patients have a higher prevalence
of glucose metabolism disorders than the general population,
as shown in the Euro Heart Survey on Diabetes and the Heart
with the Pilsen Center of Preventive Cardiology participating
as a data collection center. Patients with acute coronary
syndromes had impaired glucose tolerance in 36% and newly
diagnosed DM in 22%; these proportions were 38% and 14% inthe group of stable CHD patients [19]. That is why the oral
glucose tolerance test should be a routine procedure among
CHD patients without known T2DM [20].
Mention should also be made of the increasing rate of
prediabetes in CHD patients, e.g. metabolic syndrome or its
surrogate, hypertriglyceridemic waist, which was not docu-
mented in our analysis. Our results support the notion that the
metabolic syndrome prevalence is stable in the Czech
population (present in about a third of the population, more
in men than in women) as estimated in the Czech post-
MONICA studies [21]. However, glucose levels and waist
circumference increased, TG concentration remained stable,
but HDL-C (especially in males), atherogenic dyslipidemia, and
blood pressure were reduced, probably due to widely used
antihypertensive and lipid-lowering drugs as part of second-
ary preventive management. It should also be noted that there
is a high inter- and also intra-individual variability of fasting
TG concentrations. One has to take into account that not all
patients with high BMI and large waist circumference have the
typical insulin-resistant phenotype, i.e. abdominal fat tissue
accumulation, etc. As suggested, the prevalence of atherogenic
dyslipidemia and hypertiglyceridemic waist was also twice as
high in patients with T2DM than in those with normoglycae-
mia (20% and 38%, respectively).
Another explanation of the increasing prevalence of T2DM
and no change in prediabetes could be based on the results of
the last analysis of the landmark JUPITER study. Ridker
showed that rosuvastatin 20 mg qd may have been an
important factor increasing the prevalence of T2DM, but only
in subjects with prediabetes deﬁned as metabolic syndrome,
impaired fasting glucose, BMI ≥ 30 kg/m2, or glycated hemo-
globin (HgA1c ≥ 6% (HR 1.28; CI 1.07–1.54). For those with T2DM
risk factors, a total of 134 vascular events or deaths were
avoided for every 54 new cases of T2DM diagnosed. For trial
participants with no major T2DM risk factors, statin allocation
was associated with a 52% reduction in the primary endpoint
(HR 0.48; 95% CI 0.33–0.68; p = 0.0001), and no increase in T2DM
(HR 0.99; CI 0.45–2.21; p = 0.99) [22]. Although prescription of
statins increased more than 12 times in the EA I-IV groups of
Czech patients with CHD, and about 1/3 of patients had
prediabetes, no effect of statin therapy on T2DM prevalence
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atorvastatin 80 mg qd were only used in 2% of the Czech
patients with CHD.
The desirable level of non-HDL-C, a marker of atherogenic
potential mediated by many lipid fractions in plasma, is
≤2.6 mmol/l in patients at a very high CV risk. Although non-
HDL-C in EA IV was lower (3.2 mmol/l) than in EA I (4.2 mmol/l),
mean non-HDL-C was higher in all surveys than the
recommended one. This reﬂects the unsatisfactory achieve-
ment of the recommended level of LDL-C on the one hand, and
presence of small dense LDL particles (typical of atherogenic
dyslipidemia), increased VLDL and IDL particles on the other,
which all are not fully susceptible to statin therapy. Fibrate use
was reduced in patients with CHD in the last decade, with only
about 1% of patients receiving ﬁbrates in EA IV, although half
of all patients had T2DM (Table 1). Physicians should think
about prescribing ﬁbrates especially in diabetic patients with
overt atherogenic dyslipidemia (TG ≥2.3 mmol/l and HDL-C
<0.9 mmol/l), as demonstrated in the ACCORD-lipid trial.
Patients with T2DM and overt atherogenic dyslipidemia are at
about 70% higher relative CV risk than diabetic patients
without atherogenic dyslipidemia. Combination therapy with
simvastatin plus fenoﬁbrate reduced the relative risk of CVD
endpoints by about 30% (absolute risk of about 4.95%) in
comparison with simvastatin monotherapy [23]. In this
context, mention should also be made of the beneﬁcial effects
of fenoﬁbrate on microvascular complications in T2DM
patients [24].
However, while the prevalence of atherogenic dyslipidemia
decreased over time in all CHD patients, the AIP risk stratum
distribution remained stable. It is clear that atherogenic
dyslipidemia reﬂects only plasma TG and HDL-C concentra-
tions, whereas AIP is a more complex marker of lipid
metabolism. Logarithmic transformation of the TG/HDL-C
ratio reﬂects not only the balance between risk and protective
lipoproteins, it also correlates with lipoprotein particle size
and cholesterol esteriﬁcation rate [15]. Atherogenic index of
plasma should thus be used in clinical practice to assess the
non-LDL related CHD risk more accurately. A high AIP (over
0.24) persisted in a large proportion of patients in secondary
CHD prevention (40% males, 28% females in EA IV), particularly
in those with DM, where a high AIP (mean AIP 0.27) is
associated with a high CV risk. These results represent a major
challenge for preventive approaches in patients with CHD and
T2DM treated by standard therapy.
As shown in the paper by De Bacquer et al., the 5-year
residual risk of CV mortality was assessed in patients
participating in the EA I and II surveys. In multivariate
analysis, smoking, T-C, and fasting glucose level have been
shown to be the strongest independent modiﬁable predictors
of CV mortality [25]. Based on our data, increased glucose level
may mask the risk mediated by non-LDL-C dyslipidemia, i.e. by
atherogenic dyslipidemia, hypertriglyceridemic waist, and
particularly by AIP.
Our study has some limitations, as mentioned in the
previous paper by Mayer Jr. In brief, the Czech EUROASPIRE
patients were selected from two special cardiology centers in
Pilsen and Prague. The situation may have been even worse in
other regions of the Czech Republic. Glucose and lipid
metabolism parameters were assessed from only one venousblood sample. It is generally accepted that the intraindividual
variability of these parameters is relatively high. Treatment
with lipid-lowering drugs was used in 94% patients, statins in
most of them (93%), and this therapy might have also masked
the lipid parameters beyond LDL-C.
Conclusion
The residual risk of patients with stable CHD is still high due to
unsatisfactory treatment of conventional risk factors on the
one hand, and due to non-LDL-C dyslipidemia, particularly
glucose metabolism abnormalities, insulin resistance identi-
ﬁed by hypertriglyceridemic waist, atherogenic dyslipidemia,
non-HDL-C and, more accurately, by AIP on the other hand. It
is intriguing and not fully clear yet why hypertriglyceridemic
waist as a marker of insulin resistance, and AIP as the balance
between risk and protective lipoproteins remained stable in all
four EAs while BMI, waist circumference, glucose level, and
T2DM prevalence are increasing.
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